OptimizeRx Corporation
NASDAQOptimizeRx faces one of its sharpest analyst repricing cycles in months, with three separate target cuts landing on May 13 — the same day Q1 results were digested. The Street moved quickly after the print. Stifel maintained its Buy but pulled its target from $17 to $14. B. Riley Securities also held Buy, trimming from $11 to $10. Stephens & Co. stayed at Equal-Weight and cut from…
Snapshot as of 28 Jun 2026
OptimizeRx faces one of its sharpest analyst repricing cycles in months, with three separate target cuts landing on May 13 — the same day Q1 results were digested. The Street moved quickly after the print. Stifel…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for OPRX — free to start on ORTEX.
Sign up for free →Open OPRX on ORTEX